You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The charity also announced a partnership with Sage Bionetworks to establish an online repository for biomarker data generated by grant recipients.
Lexogen did not disclose the funding amount, but said it was one of €16 million ($17.4 million) in awards from the Austria Research Promotion Agency.
The funding, provided by the Chan Zuckerberg Initiative, will help test and study the Bay Area population in general as well as healthcare workers in particular.
For full-year 2019, the company reported total revenues of €1.1 million, down 27 percent year over year mainly due to a decrease in licensing revenue from China.
Luminist Labs is developing diagnostic technology for liver disease, which DiscernDx will integrate into its precision medicine platform.
Last month, Quest Diagnostics received Emergency Use Authorization from the US Food and Drug Administration for its SARS-CoV-2 rRT PCR test.
The platform can detect a single virus in more than 1,000 samples at a time or more than 160 viruses, including SARS-CoV-2, in a small number of samples.
The company plans to ship more than 1.3 million tests per month worldwide as production capacity increases in May.
The team will use the five-year funding to develop a liquid biopsy-based assay to select and prioritize liver cancer patients who need a liver transplant.
A single-cell RNA sequencing analysis suggests progression to multiple myeloma involves shifts in immune cell representation and activity in the microenvironment.
Waters posted revenues of $464.9 million for the quarter as the SARS-CoV-2 pandemic drove a drop in sales globally, including a 45 percent decline in China.
The company said it can now market test kits for both liquid biopsy and FFPE samples to labs in the EU and other participating geographies.
BGI will establish six so-called Huo-Yan COVID-19 testing labs in Saudi Arabia, based on the emergency lab the firm set up in Wuhan, China in February.
The firm said the assays detect all classes of alterations including genomic signatures for microsatellite instability, tumor mutation burden, and loss of heterozygosity.
The RT-PCR-based tests are designed to detect SARS-CoV-2 nucleic acid in a range of upper and lower respiratory specimens including nasal swabs and sputum.
NeoGenomics noted that test volumes had been disrupted by the COVID-19 pandemic, leading to reduced growth in the company.
The Massachusetts sequencing firm has been selling technology originally developed by Helicos BioSciences and planned to increase marketing with the IPO proceeds.
The firm said the FDA clearance was supported by data across several lab sites and all variant classes in clinical samples from 35 tumor types.
Researchers combined genome-wide association and transcriptome study data to uncover cell types affected by complex brain disorders, including Parkinson's disease.
Researchers used case and control genotypes alongside related trait, transcriptome, and population data to identify 85 cutaneous melanoma candidate loci.
The Cambridge, UK-based firm saw double-digit growth in its screening business and declines in its bioproduction and diagnostics businesses.
Last week, GenomeWeb's readers were most interested in efforts to develop assays that add samples directly to the PCR reaction without RNA extraction.
Backed by BARDA, Merck and Institute for Systems Biology are studying multiomic data to understand infection pathways and find biomarkers for symptom risk.
Illumina had sought to exclude the Harmony test from the US Market, while Ariosa had sought to overturn the jury verdict with a post-trial maneuver.
The partners will specifically integrate Gilson's Trackman Connected digital bench tools and Qiagen's manual nucleic acid extraction kits.
According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.
CNBC reports that the CDC Director says a SARS-CoV-2 vaccine isn't likely to be generally available until the third quarter of 2021, timing President Donald Trump disputes.
Michael Caputo, the top Department of Health and Human Service spokesperson, is taking a leave of absence, CNN says.
In Nature this week: MassIVE.quant resource houses mass spectrometry-based proteomic data, influence of Viking genetics on European populations, and more.